Ignite Creation Date:
2024-05-05 @ 5:06 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00386139
Status:
COMPLETED
Last Update Posted:
2017-02-07
First Post:
2006-10-09
Brief Title:
A Safety and Efficacy Trial of the Combination of Aliskiren Hydrochlorothiazide HCTZ300125 mg and 30025 mg Compared to Aliskiren 300 mg in Hypertensive Patients
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren HCTZ 300125 mg and 30025 mg in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the diastolic blood pressure lowering effect of combination of aliskiren 300 mg and HCTZ 125 mg and 25 mg in hypertensive patients who do not show sufficient blood pressure response to aliskiren 300 mg
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None